GENE ONLINE|News &
Treeline Biosciences Advances Three Cancer Drugs to Phase 1 Trials and Secures $200 Million Funding
Treeline Biosciences, a biotechnology company co-founded by Josh Bilenker, former Loxo Oncology founder, and Jeff Engelman, a former Novartis executive, has announced the advancement of three cancer drug candidates into Phase 1 clinical trials. The company also disclosed it has secured $200 million in new funding to support its ongoing research and development efforts.
The three investigational drugs target various forms of cancer and represent Treeline’s first clinical candidates since its inception. While details about the specific mechanisms or therapeutic areas of these drugs remain limited, their progression to early-stage human trials marks a significant milestone for the startup. The announcement coincides with Treeline’s successful fundraising round, which brings additional financial resources to further its pipeline and operational goals.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
Date: September 3, 2025
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Hilton Partners With Big Brothers Big Sisters to Provide Hospitality Career Training for Youth
2026-06-18
Pacific Life Launches Income Horizon Collective Investment Trust Series for Retirement Plans
2026-06-18
Synovis Micro Companies Alliance to Distribute MediThinQ SHIYA 3D Visualization Platform Globally
2026-06-18
Diamond Estates Wines & Spirits Inc. Renews Investor Relations Agreement with Atrium Research
2026-06-18
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
